Core Insights - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls, surpassing Regeneron Pharmaceuticals' previous offer of $256 million in a bankruptcy auction [1][2] - The deal is expected to close soon, pending a court hearing scheduled for June 17 [1] - 23andMe filed for bankruptcy in March due to declining demand and a data breach in 2023 that compromised sensitive customer information [2][6] Company Developments - 23andMe's bankruptcy filing was a result of a significant decline in consumer demand for DNA testing services [2][6] - The company faced legal challenges, with New York and over two dozen other states suing to contest the sale of its customers' private information [3] - TTAM Research Institute, associated with Wojcicki, has committed to upholding 23andMe's existing privacy policies and complying with data protection laws [2] Competitive Landscape - Regeneron Pharmaceuticals initially offered $256 million for 23andMe, which was later outbid by Wojcicki's nonprofit [1][5] - Regeneron expressed willingness to make a new bid but requested a $10 million breakup fee if Wojcicki's bid is accepted [5]

If there was ever a Dow Industrials stock that should be labeled "buy and hold at your own risk," it is Cisco Systems, Inc. (NASDAQ: CSCO ). I can't think of a stockI'm Rob Isbitts, founder of Sungarden Investment Publishing. I run the new investing group Sungarden Investors Club, a community dedicated to navigating the modern investment climate with humility, discipline, and a non-traditional approach to income investing. I've been charting investments since the 1980s, and I spent decades an an investment ...

Shares of defense contractor Lockheed Martin (LMT 3.51%) rallied 3.5% on Friday, even though the S&P 500 (^GSPC -1.13%) was down 1.1%.Lockheed and major defense contractors were up today after Israel struck Iran this morning, raising the prospect of a regional war. That sent oil prices up and most stocks down; however, the prospect that Israel or the U.S. may buy more equipment from Lockheed sent the stock of the leading defense contractor upwards.Israel and Lockheed have historyLockheed Martin's stock actu ...

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the "Company" or "Osisko Metals") (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: OB51) announces that, effective June 13, 2025, the Company has been continued from British Columbia (Business Corporations Act (British Columbia) to Ontario (Business Corporations Act (Ontario)) (the "Continuance"). The Company adopted new articles and by-laws as part of the Continuance, which replaced the prior articles and by-laws of the Company. The Continuance and ...

Not for Distribution to U.S. Newswire Services or for Dissemination in the United States of America. TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- Picton Mahoney Asset Management (“Picton Mahoney”) announced that, effective today, it has renamed the funds set forth below in order to streamline the names across its fund family. Mutual FundsPrevious NameNew NamePicton Mahoney Fortified Equity FundPICTON Global Equity FundPicton Mahoney Fortified Income FundPICTON Income FundPicton Mahoney Fortified Core Bond Fun ...

MONTRÉAL, June 13, 2025 (GLOBE NEWSWIRE) -- Bombardier Inc. (“Bombardier”) today announced that it has redeemed US$500 million principal amount of its outstanding 7.875% Senior Notes due 2027 (the “Redemption Notes”) as set forth in the notice of partial redemption issued May 14, 2025. Payment of the redemption price and surrender of the Redemption Notes for redemption are being made through the facilities of the Depository Trust Company in accordance with the applicable procedures of the Depository Trust C ...

HOUSTON, June 13, 2025 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a Bitcoin First Company and global leader in sustainable energy management, announced today that it will effect a 1-for-8 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on June 23, 2025. KULR’s common stock will continue to trade on the NYSE-American Market under the symbol “KULR” and under a new CUSIP numb ...

Hello and welcome to my Seeking Alpha page. My name is Jack Elias, and I am a dedicated business student with a fervent passion for the world of investing. With a solid foundation in both theoretical knowledge and practical experience, I bring a unique perspective to the realm of financial analysis.My journey into the world of investing began during my undergraduate studies in Finance at Arizona State University, where I developed a keen interest in dissecting financial markets and evaluating investment opp ...

Group 1 - Huntsman shares are yielding above 9% based on its quarterly dividend, with the stock trading as low as $10.98 [1] - Historically, dividends have contributed significantly to the total return of the stock market, exemplified by the iShares Russell 3000 ETF, which saw a 0.6% decrease in share price over twelve years but provided $10.77 per share in dividends, resulting in a total return of 13.15% [1] - Collecting a yield above 9% is considered attractive if sustainable, especially when compared to the average annual total return of about 1.0% from reinvested dividends [1] Group 2 - Dividend amounts are unpredictable and typically fluctuate with company profitability, making historical performance important for assessing future dividend sustainability [2]

Company Overview - GeneDx Holdings Corp. is a biotechnology company that specializes in clinical diagnostic services for rare and pediatric genetic disorders [3]. Allegations of Wrongdoing - Grizzly Research published a report on February 5, 2025, alleging that GeneDx is committing widespread fraud, claiming that the company's growth is largely an illusion driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to artificially inflate revenue [4]. - The report accuses GeneDx of using an illegal practice known as "code stacking" to inflate its revenue [4]. - It is suggested that GeneDx executives, including CEO Katherine Stueland and CFO Kevin Feeley, may be aware of imminent risks, as they have consistently sold their shares immediately upon vesting without engaging in open market purchases [4]. Stock Market Reaction - Following the publication of the report, GeneDx's stock price fell by $4.84 per share, or 6.72%, closing at $67.18 per share on February 5, 2025 [4].